Company Description
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.
Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.
The company is based in Tortola, British Virgin Islands.
| Country | VG |
| Founded | 1973 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Ian B. Walters M.B.A., M.D. |
Contact Details
Address: Clarence Thomas Building, P.o. Box 4649, Road Town Tortola, D8 VG1110 Virgin Islands, British | |
| Phone | 416-737-7600 |
| Website | portagebiotech.com |
Stock Details
| Ticker Symbol | PRTG |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001095435 |
| CUSIP Number | G7185A128 |
| ISIN Number | VGG7185A1286 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ian B. Walters M.B.A., M.D. | Chief Executive Officer and Chairman of Board |
| Allan J. Lee Shaw CPA | Chief Financial Officer |
| Dr. Robert A. Kramer Ph.D. | Chief Scientific Officer |
| Brian Wiley | Chief Business Officer |
| Justin Fairchild | Vice President of Development |
| Joseph Ciavarella | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 424B3 | Prospectus |
| Apr 12, 2024 | 6-K | Report of foreign issuer |
| Mar 8, 2024 | 424B3 | Prospectus |
| Mar 8, 2024 | 6-K | Report of foreign issuer |
| Mar 7, 2024 | 424B3 | Prospectus |
| Mar 7, 2024 | 6-K | Report of foreign issuer |
| Feb 29, 2024 | 6-K | Report of foreign issuer |
| Feb 28, 2024 | 424B3 | Prospectus |
| Feb 28, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |